US court denies Provenge supporters' appeal
This article was originally published in Scrip
A US federal appeals court has declined to reinstate a patient advocacy group's lawsuit challenging the FDA's refusal to approval Dendreon's novel prostate cancer vaccine Provenge (sipuleucel-T). The court affirmed a November ruling by an Ohio federal judge, who said Care to Live's claims against three federal officials and an FDA advisory panel member who voted against recommending Provenge for approval were not ripe for adjudication because the agency has not taken final action on the BLA. In May 2007 the FDAissued a "complete response" letter to Dendreon requesting additional data to support the vaccine's efficacy. Care to Live – which represents cancer patients, families, doctors, investors and advocates – sued the agency, alleging that political infighting impacted the agency's decisions. Care to Live's website said the group will petition the Supreme Court for review.
You may also be interested in...
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Although US FDA wants sponsors to maintain blinded Phase III follow-up as long as possible after emergency use authorization or licensure, vaccine researcher Larry Corey says it will become ‘untenable’ to keep individuals in placebo arm once they qualify for vaccine access under the allocation framework.
Industry principles for enhancing diversity in clinical trials call for use of digital data collection tools and flexible scheduling of study site visits to reduce barriers to enrollment, as well as greater involvement of under-represented communities in the trial design planning process and recruitment of investigators with diverse ethnic and racial backrounds.